Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)
Part of paid clinical trials in Gainesville, Florida.
- Sponsor
- University of Florida
- Study ID
- NCT05322850
- Phase
- PHASE1/PHASE2
- Status
- Recruiting
Conditions
- Acute Lymphoid Leukemia
- Acute Myeloid Leukemia
- Acute Undifferentiated Leukemia
- Chronic Myeloid Leukemia - Accelerated Phase
- Chronic Myeloid Leukemia in Lymphoid Blast Crisis (Diagnosis)
- Chronic Myeloid Leukemia in Myeloid Blast Crisis
- Mixed Phenotype Acute Leukemia
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - 50 Years
- Healthy Volunteers
- Accepted
Interventions
- Orca-Q — BIOLOGICALAll transplant recipients enrolled on this study in both the phase I and phase II portions will receive Orca-Q (Orca-Q Prime and Orca-Q Supplement) intravenously following myeloablative conditioning.
Study Details
This is a first in children prospective study of allogeneic hematopoietic cell transplant using a centrally manufactured engineered donor graft (Orca-Q). The study will assess safety and efficacy of Orca-Q in pediatric patients with hematologic malignancies.
Key Dates
- First listed
- Apr 12, 2022
- Start date
- Aug 16, 2022
- Status verified
- Aug 2026
- Primary completion
- Sep 30, 2026
- Completion
- Sep 30, 2027
Study Design
- Enrollment
- 40 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Orca-Q
Primary Outcome Measure
Primary graft failure [ Time Frame: 28 days ]
Central Contacts
- Alex Leggett, MS352-273-9785
Locations (4)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Florida | Gainesville | Florida | 32608 | Jordan Milner, MD (PRINCIPAL_INVESTIGATOR) |
| Nicklaus Children's Hospital | Miami | Florida | 33155 | - |
| University of Miami | Miami | Florida | 33136 | - |
| Johns Hopkins All Children's Hospital | St. Petersburg | Florida | 33701 | - |
Find similar trials in Gainesville, FL
By condition
By specialty
Related Studies
- A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic MalignanciesPHASE1 · Recruiting · Orca Biosystems, Inc. · Duarte, California
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyPHASE3 · Recruiting · Children's Oncology Group · Birmingham, Alabama
- Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)PHASE2 · Recruiting · Fred Hutchinson Cancer Center · Tampa, Florida
- A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 MutationPHASE1/PHASE2 · Recruiting · Syndax Pharmaceuticals · Aurora, Colorado